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Materials and Methods 
Materials and instrumentation 
Solvents and reagents were ordered from Sigma Aldrich, TCI, Aurum, or Alfa Aesar and used 
without further purification. GC-FID data were collected on Shimadzu GC-17A and Agilent 7820A 
GC systems. GC-MS data were collected on a Shimadzu GCMS-QP2010 SE and Agilent 7820A 
with 5977B MSD. 1H NMR, 11B NMR, and 13C NMR spectra were recorded on a Bruker Prodigy 
400 MHz instrument; 1H NMR spectra were recorded at 400 MHz, 11B NMR spectra were recorded 
at 128 MHz, and 13C NMR spectra were recorded at 101 MHz. For 1H NMR and 13C NMR, 
chemical shifts were normalized to the deuterated solvent’s proto impurity (CHCl3: 1H NMR 7.26 
ppm, 13C NMR 77.16 ppm; DMSO-d5: 1H NMR 2.50 ppm, 13C NMR 39.52 ppm). 19F NMR were 
recorded on a Varian 300 MHz instrument; 19F NMR spectra were recorded at 282 MHz.  
Site-saturation library construction 
Site-saturation mutagenesis was performed using the 22-codon method.1 Two methods were 
used for primer design and cloning: kinase-ligase-DpnI (KLD) (New England Biolabs) and Gibson 
assembly. In KLD cloning, primers were designed for blunt-end cloning with the KLD kit, where 
the degenerate codons were placed at the blunt end. The PCR product was then ligated via the 
KLD enzyme mix for 1 hour and used to transform electrocompetent cells. In the second 
approach, primers were designed for Gibson assembly, with the degenerate codons placed within 
either the forward or reverse primer. Two PCRs were performed for each library, the first 
containing a mixture of degenerate primers (12:9:1 NDT:VHG:TGG) and the second containing a 
reverse primer with a complementary overhang to the degenerate primer. The second primer for 
each PCR is located in the ampicillin cassette to select against off-target PCR products. The two 
PCR products were gel-purified with the Zymoclean Gel DNA Recovery Kit (Zymo Research Corp, 
Irvine, CA) and ligated together via Gibson assembly, followed by transformation (Transformation 
of genes). 
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Transformation of genes 
Electrocompetent Escherichia coli (E. coli, E. cloni EXPRESS BL21(DE3) cells, Lucigen, 
Middleton, WI) were transformed with Gibson assembly products using a Gene Pulser Xcell (Bio-
Rad, Hercules, CA). SOC medium (750 µL) was added, and the cells were plated on LB-ampicillin 
(100 µg mL−1) (LB-amp) agar plates. Overnight cultures (5 mL LB-amp in culture tubes) were 
grown at 37 °C and 230 rpm for 12–18 hours. Overnight cultures were used to inoculate flask 
cultures, prepare glycerol stocks, and isolate plasmids. Plasmids were isolated with Qiagen 
Miniprep kits, and the genes were sequence-verified (T7 promoter / terminator sequencing 
primers, Laragen, Inc.). 
96-Well plate library expression 
Single colonies from the LB-amp agar plates were picked using sterile toothpicks and grown in 
400 µL LB-amp in 2-mL 96-well deep-well plates at 37 °C, 250 rpm, 80% humidity overnight (12–
18 hours). Multi-channel pipettes were used to transfer 50 µL of starter culture into deep-well 
plates containing 1 mL Hyperbroth (AthenaES) with 100 µg mL−1 ampicillin (HB-amp) per well. 
The deep-well expression culture plate was incubated at 37 °C, 250 rpm, 80% humidity for 2.5 
hours. The plate was then chilled on ice for 30 minutes. Expression of the protein of interest was 
induced with isopropyl-β-D-thiogalactoside (IPTG) and cellular heme production was increased 
with 5-aminolevulinic acid (ALA); an induction mixture containing IPTG and ALA in HB-amp (50 
µL) was added to each well for a final concentration of 0.5 mM IPTG and 1 mM ALA, 1.1 mL 
culture volume. The plate was incubated at 22 °C and 250 rpm overnight.  
96-Well plate reactions and screening  
96-Well deep-well plates containing E. coli expressing a protein variant were centrifuged at 4000 
× g for 10 minutes at 4 °C. The supernatant was discarded, and pellets were resuspended in 
nitrogen-free M9 minimal media (M9-N, 380 µL) and brought into a Coy vinyl anaerobic chamber 
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(0–20 ppm O2). To each well was added 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (1) (10 
µL, 400 or 800 mM in ethanol) and EDA (2) (10 µL, 400 or 800 mM in ethanol) and sealed with 
an adhesive foil cover. The reactions were shaken in the Coy chamber at room temperature for 
16 hours. The plate was then removed from the Coy chamber and the reactions were worked up: 
to each reaction internal standard (20 mM 4-methyl anisole in 1:1 hexane:ethyl acetate, 20 µL) 
and 1:1 hexane:ethyl acetate (480 µL) were added. A silicone plate sealing mat (AWSM1003S, 
ArcticWhite) was used to cover the plate, and the plate was vortexed. The plate was then 
centrifuged (4000 × g, 10 minutes) and the organic layer was transferred to GC vial inserts in GC 
vials. The samples were assayed for product formation via GC.  
Wells with improved activity relative to the parent protein were streaked out onto LB-amp agar 
plates. A single colony from the plate was picked and grown in 5 mL LB-amp overnight (230 rpm, 
37 °C). These overnight cultures were used in flask protein expression and small-scale 
biocatalytic reactions to verify enhanced activity and/or selectivity relative to the parent sequence. 
Medium- and large-scale protein expression  
Cultures of 50 mL HB-amp  (50 mL in 250-mL unbaffled flasks or 1 L in 2.8-L unbaffled flasks) 
were inoculated 1% (v/v) with saturated overnight cultures and shaken in an Inova 42 shaker at 
230 rpm, 37 °C or an NFors shaker at 160 rpm, 37 °C. At an approximate OD600 of 1.0 – 1.2, 
cultures were chilled on ice for 30 minutes. Protein expression was induced with 1 M IPTG to a 
final concentration of 0.5 mM, and heme production was enhanced with supplementation of 1 M 
ALA to a final concentration of 1 mM. The cultures were shaken in an Inova 42 shaker at 230 rpm 
(160 rpm for NFors) at 22 °C overnight (18–24 hours). Cells were transferred to 50-mL Falcon 
tubes or 500-mL centrifuge buckets and pelleted via centrifugation at 4000 × g for 10 minutes at 
4 °C.  
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Lineage validation reactions 
Small-scale reactions were set up in 2-mL GC crimp vials. E. coli expressing the appropriate 
heme protein catalyst (380 µL, adjusted to the appropriate optical density with 20 mM MOPS 
buffer, pH=7) was added to the vials; the vials were then brought into a Coy anaerobic chamber 
(0 – 20 ppm O2). To each vial was added 1 (10 µL in ethanol, final concentration 20 mM) followed 
by 2 (10 µL in ethanol final concentration 40 mM). Directly following addition of 2, the reaction vial 
was crimped and shaken at 500 rpm at room temperature. Reactions were worked up for GC 
analysis. For GC analysis, 20 µL 100% ethanol and an internal standard (20 µL 4-ethyl anisole, 
20 mM in 1:1 hexane:ethyl acetate) were added to the vial. A 1:1 mixture of hexane:ethyl acetate 
(480 µL) was added, and the reaction was transferred into 1.7-mL Eppendorf tubes for extraction. 
The liquid-liquid extraction was carried out with a Retsch MM 301 mixing mill (1 minute, 30 Hz / 
1800 rpm). Samples were centrifuged at 20817 × g for 5 minutes at RT, and the organic layer 
was used for chromatographic analysis.  
 
Sonicated lysate preparation and hemochrome assay 
An aliquot of cells adjusted to a density of OD600= 30 for protein concentration determination was 
sonicated (QSonica Q500 Sonicator, 1/8 in tip) for 4 minutes, 1 second on, 1 second off at 30% 
amplitude. Following sonication, a 0.1 volume equivalent Bugbuster 10X protein extraction 
reagent (EMD Millipore) was added; the lysate-Bugbuster mixture was incubated 15 minutes at 
room temperature to improve cell lysis. The sonicated lysate was clarified via centrifugation at 
20817 × g and 4 °C for 10 minutes. The concentration of heme-loaded protein was determined 
with the pyridine hemochromagen (hemochrome) assay.2 Briefly, sonicated and clarified lysate 
(500 µL) was added to a cuvette. 500 µL of solution I (0.2 M NaOH, 40% (v/v) pyridine, 500 µM 
potassium ferricyanide) were added, and the spectrum of this oxidized sample was taken from 
350 – 600 nm. Sodium dithionite (10 µL of 0.5 M solution in 0.5 M NaOH) was added, and the 
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reduced spectrum was taken from 350 – 600 nm. The pyridine hemochromagen concentration 
was determined using its Q bands, with the literature extinction coefficient of 23.98 mM−1 cm−1 for 
(557 nmreduced – 540 nmoxidized). 
Preparation of lyophilized whole-cell biocatalysts 
Cultures of 1 L HB-amp in unbaffled 2.8-L Erlenmeyer flasks were inoculated 1% (v/v) with 
saturated overnight cultures and shaken in an Infors shaker at 160 rpm, 37 °C. At an approximate 
OD600 of 1.0, cultures were chilled on ice for 30 minutes. Protein expression was induced with 1 
M IPTG to a final concentration of 0.5 mM, and heme production was enhanced with 
supplementation of 1 M ALA to a final concentration of 1 mM. The cultures were shaken in an 
Infors shaker at 230 rpm and 22 °C overnight (18–24 hours). Cells were transferred to 500-mL 
centrifuge buckets and pelleted via centrifugation at 4000 × g for 10 minutes at 4 °C. The pellet 
was transferred into a 50-mL Falcon tube and flash-frozen on powdered dry ice. The lid of the 50-
mL Falcon tube was replaced by a Kimwipe held on with a rubber band and put in a lyophilization 
bottle. Pellets were lyophilized for at least 36 hours on a Labconco 4.5 plus freezone benchtop 
lyophilizer (Labconco, Kansas City, MO) to ensure complete lyophilization. Following 
lyophilization, the cells were transferred into a sealable plastic bag and ground into a fine powder 
using a mortar and pestle. The lyophilized cell powder was stored at -20°C until use. 
 
Preparative-scale biocatalytic reactions with lyophilized whole cells 
To a 250-mL round-bottom flask, lyophilized whole cells harboring RmaNOD THRAW (500 mg, 
10 mg mL-1 final loading) were added, and the catalyst was reconstituted in aqueous buffer (KPi 
50 mM pH 7.5, 37.6 mL) by stirring for 10 minutes. The round-bottom flask was sealed with a 
septum and cycled with Argon and vacuum three times. To the reconstituted catalysts 2 (174.8 
µL neat substrate, 1 mmol, final concentration 20 mM) was added. Using a syringe pump, EDA 
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solution (5 mL EtOH, 7 mL dH2O, 241.8 µL EDA, solution concentration 163 mM, final 
concentration 40 mM) was added over a period of 2 hours, using a long Luer lock needle such 
that the needle sat below the solution surface during addition. The reaction was stirred at room 
temperature overnight (16-hour total reaction time). Upon reaction completion the reaction mixture 
was stored at -20 °C until workup.  
 
Procedure for column-free purification of trifluoroborated product (4) 
The trifluoroboration procedure was adapted from Bagutski et al.3 Following completion of the 
reaction, the product was extracted three times with 1:1 hexane:ethyl acetate (1 volume 
equivalent per extraction). Deprotected boronic acid was reprotected by stirring the organic layer 
with pinacol (236 mg, 2 mmol, 2.0 equivalents) in the presence of magnesium sulfate (1 g). The 
solution was filtered to remove magnesium sulfate and concentrated in vacuo to remove solvent 
and remaining unreacted starting material (1). The crude reaction mixture was then resuspended 
in 1:1 methanol:water (8 mL total). Potassium bifluoride solution (1.67 mL of 3 M solution in water, 
5.0 equivalents) was added dropwise, and the reaction was left to proceed overnight. The solution 
was concentrated in vacuo to remove methanol, flash-frozen, and lyophilized to remove water. 
Acetone (20 mL) was added to the 40-mL scintillation vial containing the lyophilized crude product. 
The product was resuspended in the sealed scintillation vial via sonication bath. The solution was 
vacuum filtered, and the vial was washed three times with acetone (10 mL). The acetone was 
removed in vacuo, and the product was dried on high vacuum. 
 
Determination of initial cyclopropanation activity 
A panel of heme proteins previously engineered for carbene or nitrene transfer reactions4 was 
tested for their activity in formation of 3; proteins included in these tests were expressed in 96-
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well plates (96-Well plate library expression). The cell pellets were resuspended with 400 µL 1x-
M9-N, and the 96-well deep-well plates were brought into a Coy anaerobic chamber. A substrate 
solution (50 µL of 180 mM 1 and 2, 20 mM final concentration of each substrate) was added to 
each well. The plates were sealed with an adhesive foil cover and shaken at 500 rpm and room 
temperature for 6 hours. The foil covers were removed, 500 µL cyclohexane were added to each 
well, and the plates were sealed with silicone sealing mats and vortexed for 1 minute. The organic 
layer was transferred to GC vial inserts in GC vials, and formation of 3 was analyzed via GC-MS.  
The highest initial activity for cis-selective cyclopropanation was exhibited by ApePgb W59A 
Y60G F145W and its intermediate variants. The highest initial activity for trans-selective 
cyclopropanation was produced by RmaNOD Q52A, RmaNOD Q52V, and Mb H64V V68A; 
ApePgb W59A Y60G F145W and RmaNOD Q52V were variants engineered for unactivated 
alkene cyclopropanation.5 The myoglobin was engineered by the Fasan lab for styrenyl alkene 
cyclopropanation reactions.6 
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Table S1. Protein scaffolds tested for formation of 3 in the initial-activity screening. 
UniProt ID of 
wild type 
Organism Annotation Number of variants 
tested 
Formation of 3 
B3FQS5 Rhodothermus 
marinus 
Cytochrome 
c 
9 Trace detected 
P15452 Hydrogenobacter 
thermophilus 
Cytochrome 
c-552 
2 n.d. 
P00080 Rhodopila 
globiformis 
Cytochrome 
c2 
2 n.d. 
D0MGT2 Rhodothermus 
marinus 
Nitric oxide 
dioxygenase 
10 Detected 
P02185 Physeter catodon Myoglobin 1 Detected 
B3DUZ7 Methylacidiphilum 
infernorum 
Hell’s gate 
globin 
2 Trace detected 
O66586 Aquifex aeolicus Thermoglobin 1 Trace detected 
G7VHJ7 Pyrobaculum 
ferrireducens 
Protoglobin 1 Trace detected 
Q0PB48 Campylobacter 
jejuni 
Truncated 
hemoglobin 
1 n.d. 
Q9YFF4 Aeropyrum pernix Protoglobin 10 Detected 
O31607 Bacillus subtilis Truncated 
hemoglobin 
1 n.d. 
P14779 Bacillus 
megaterium 
Cytochrome 
P450BM3 
50 n.d. 
 
Table S2. Activity of top variants from initial screening. Activity is given as integrated area for the 
target ions 182 m/z and 195 m/z. *Variant was found during protein engineering for the referenced 
project. n.d.: not detected in given ion channel. 
Variant Reference cis (182 m/z) trans (182 m/z) cis (195 m/z) trans (195 m/z) 
ApePgb WT 5 122 n.d. n.d. n.d. 
ApePgb Y60G 5 1865 n.d. n.d. n.d. 
ApePgb Y60G 
F145N 
5* 32478 896 2620 1314 
ApePgb W59A 
Y60G 
5 5375 n.d. 351 n.d. 
ApePgb W59A 
Y60G F145W 
5 30043 n.d. 2513 204 
Mb H64V V68A 6 423 1095 n.d. 1437 
RmaNOD WT 5 n.d. 576 n.d. 251 
RmaNOD 
Q52V 
5 193 1039 n.d. 1074 
RmaNOD 
Q52A 
5* n.d. 1417 n.d. 1767 
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Calibration curves for analytical-scale concentration determinations 
To generate a calibration curve for analytical-scale reactions, solutions at varying concentrations 
of the cyclopropane authentic standard were prepared in E. coli cell resuspensions (20 mM 
MOPS, pH = 7.01, 4.8% ethanol, OD600 = 28 for cis-3, OD600 = 30 for trans-3). Two 420-µL aliquots 
of each solution at each concentration were worked up following the protocols in Small-scale, 
whole-cell biocatalytic reaction preparation and work-up, skipping the addition of 20 µL 100% 
EtOH, and the worked-up sample was analyzed by GC-MS. The y-axis of each calibration curve 
gives the product:internal standard ratio, calculated as total ion count (TIC) of the GC-MS peak 
corresponding to the target product divided by the TIC of the GC-MS peak corresponding to the 
internal standard. The x-axis of each calibration curve is the concentration corresponding to the 
product:internal standard ratio. The resulting calibration curves reproducibly display non-linearity, 
in which low concentrations of cyclopropane show a diminished response. While this indicates a 
product loss event, the standard curve reproducibility shows that it can be utilized to reliably 
calculate analytical-scale yields after fitting with an exponential function.  
Protein Engineering Strategies 
Cis-selective lineage 
As ApePgb AGW was the most cis-diastereoselective variant with good activity, it was selected 
as the initial parent enzyme for the cis-selective lineage. Single-site-saturation libraries were 
generated for ApePgb AGW at active-site residues 63, 86, and 90. Hits (wells identified to have 
enhanced activity) were identified in screening, but subsequent validation of protein variants 
identified as hits in screening failed to verify improved variants. At this point, we would typically 
target additional active-site residues for mutagenesis. In parallel, however, screening RmaNOD 
Q52A for enhanced trans-cyclopropylboronate activity yielded variant RmaNOD Y32T Q52A with 
420 TTN and an inversion of diastereoselectivity from 17:83 cis:trans to 90:10 cis:trans. We 
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determined that RmaNOD Y32T Q52A produced the same cis enantiomer as ApePgb AGW with 
five-fold higher cis-3 formation, and therefore used RmaNOD Y32T Q52A as the parent protein 
for further evolution on the cis-selective lineage. The crystal structure solved for the related protein 
variant, RmaNOD Q52V, was used to select sites for mutagenesis (Figure S1). 
 
 
Figure S1. Amino-acid residues targeted in the cis-selective RmaNOD evolutionary lineage. The 
α-carbons of the five fixed mutations relative to RmaNOD WT (Y32T, Y39H, L48R, Q52A, and 
R79W) are shown as blue spheres. The α-carbons of other residues investigated as part of the 
cis- lineage are shown as green spheres. 
 
As we had thus far only targeted a small subset of the active-site residues, in order to screen a 
larger sequence space without increasing the overall screening time with a medium-throughput 
GC-based screening method, we opted to reduce redundancy by screening 44 clones per library 
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rather than 88. Screening only 44 clones for a 22-member library still has an 86% probability of 
full library coverage (compared to 98% probability for 88 clones per library) while allowing for 
higher sequence space coverage (Figure S2).  
 
Figure S2. Representative 96-well screening plate layout for screening two libraries per plate. 
Using RmaNOD Y32T Q52A as parent, in a second round of site-saturation mutagenesis we 
targeted residues M31, F36, Y39, F46, L48, P49, I53, L56, R79, R86, V89, and L101, screening 
one half-plate (44 colonies) per library.  This round of engineering yielded hits at positions 39, 48, 
79, and 86. Residues 39 and 48 are in the distal heme pocket. R79 and R86 coordinate with the 
heme carboxylate; the underlying cause for the activity enhancement at these positions is unclear. 
It is noteworthy that the mutations at R79 significantly enhanced activity at the cost of 
diastereoselectivity, while mutation of residues 39 and 48 enhanced diastereoselectivity with no 
significant effect on activity. We therefore recombined the mutations at these positions. The 
combination of mutations Y32T, Y39H, L48R, Q52A, and R79W was found under screening 
conditions to both improve activity and stereoselectivity. 
Trans-selective lineage 
Site-saturation mutagenesis libraries were generated at positions 31, 36, 46, 49, 53, 56, 79, 89, 
and 101, using RmaNOD Q52A as the parent sequence and the crystal structure of RmaNOD 
Q52V to guide site selection (Figure S3). As with the cis- lineage, we screened 44 colonies per 
library for this and all future site-saturation mutagenesis libraries in the trans- lineage. By 
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screening these libraries, we identified mutation L101N, which improved diastereoselectivity for 
the trans- product without significantly affecting enzyme activity. 
  
 
Figure S3. Amino-acid residues targeted in the trans-selective RmaNOD evolutionary lineage. 
The α-carbons of the six fixed mutations relative to RmaNOD WT (L20W, Q52A, L56I, L60H, 
L101N, and I105M) are shown as blue spheres. The α-carbons of other residues investigated as 
part of the trans- lineage are shown as green spheres.  
In the next round of evolution, site-saturation mutagenesis libraries were generated at positions 
35, 42, 53, 56, 60, 79, 96, 97, and 125, using RmaNOD Q52A L101N as the parent sequence. 
From this second round of site-saturation mutagenesis, beneficial mutations were identified at 
positions 56 and 60, with the optimal mutation (defined as boosting activity the most while 
retaining diastereoselectivity) was identified as L60H.  
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Because the activity of RmaNOD Q52A L60H L101N was still very low, we continued with two 
further rounds of site-saturation mutagenesis. Using RmaNOD Q52A L60H L101N as the parent 
sequence, in the first round, we targeted positions 27, 28, 43, 47, 48, 55, 59, 94, 105, 111, and 
121, identifying beneficial mutations at positions 55 and 105. We decided to move forward with 
the mutation I105M. In the final round of site-saturation mutagenesis, we targeted positions 16, 
19, 20, 23, 24, 27, 28, 31, 36, 46, 49, 56, 79, 98, 100, 108, 109, 112, 117, and 118, now using 
RmaNOD Q52A L60H L101N I105M as the parent sequence. From these libraries, we identified 
mutations L20W, M31F, L56A, and L56I, all of which boosted activity of the enzyme. By 
constructing and screening a recombination library of these four mutations, we identified 
RmaNOD L20W Q52A L56I L60H L101N I105M as the combination with the greatest increase in 
activity, while maintaining near-perfect diastereoselectivity.  
Protein Crystallography 
Cloning, expression, and purification of for crystallography 
DNA encoding RmaNOD Q52V was subcloned into a pET22b vector backbone encoding an N-
terminally His-tagged SUMO fusion through PCR amplification and Gibson assembly7 to generate 
“pSUMO RmaNOD Q52V”. BL21(DE3) E. cloni express E. coli cells (Lucigen) were transformed 
with pSUMO RmaNOD Q52V. A single colony was used to start an overnight culture in LB-amp, 
which was grown overnight at 37 °C, 230 rpm. HB-amp (1 L in an unbaffled 2.8-L flask) was 
inoculated with 1% (v/v) overnight culture and shaken at 37 °C, 160 rpm (NFors shaker). At OD600 
= 1.0 the flask was put on ice for 30 minutes, induced with final concentration of 0.5 mM IPTG, 
and supplemented with a final concentration of 1 mM 5-ALA. The culture was shaken overnight 
at 22 °C, 160 rpm. Following expression, the culture was centrifuged at 4000 × g for 10 minutes 
at 4 °C and frozen at -20 °C. 
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The pellet was thawed on ice and resuspended in resuspension buffer (25 mM Tris pH 7, 100 mM 
NaCl). The cells were lysed via sonication (QSonica Q500 Sonicator). The lysate was clarified via 
centrifugation (15 minutes, 20817 × g) and filtered through 0.22-µm filters. The protein was 
purified on an Akta purifier (GE Healthcare) with a 1-mL HisTrap column running a linear gradient 
between resuspension buffer (25 mM Tris pH 7, 100 mM NaCl, 20 mM  imidazole) and elution 
buffer (25 mM Tris pH 7, 100 mM NaCl, 500 mM imidazole). Fractions containing protein of 
interest were pooled and buffer exchanged into 25 mM Tris pH 7, 25 mM NaCl, 5 mM DTT. His-
tagged Ulp1 protease (a gift from Christopher Bley, Hoelz lab) was added, and the proteolysis 
was allowed to proceed overnight. Following proteolysis, the sample was passed through two 
hand columns with Nickel-NTA agarose bulk resin (Qiagen) to remove the cleaved His-tagged 
SUMO and His-tagged Ulp1 protease. The flow through containing the protein of interest was 
buffer exchanged and concentrated in 25 mM Tris pH 7, 25 mM NaCl buffer, and flash-frozen in 
aliquots. 
 
Protein crystallization 
Sparse-matrix screens were set up using 0.2 µL protein and 0.2 µL well solution using a Gryphon 
robotic platform (Art Robbins Instruments). Quasicrystals were found in Crystal HT G10 (Hampton 
Research, 50 mM Cd(II)SO4, 0.1 M HEPES pH 7.5, 1.0 M sodium acetate trihydrate). Testing 
other divalent metal salts resulted in Cu(II)SO4 as an equivalent replacement for the cadmium 
salt. Refining from this condition using 24-well sitting-drop well plates (Hampton Research), 2 µL 
protein solution and 2 µL well solution yielded crystals in approximately one week in 40 mM 
Cu(II)SO4, 0.1M HEPES pH 7.6, 1.2 M sodium acetate trihydrate. These crystals were 
cryoprotected with well solution supplemented with glycerol (increased by steps of 5% 
sequentially up to 25% final concentration glycerol) and flash-frozen in liquid nitrogen. 
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Data collection and refinement 
Diffraction data were collected on the Stanford Synchrotron Radiation Laboratory Beamline 12-2. 
As there are no previously reported structures for the RmaNOD scaffold, the data were collected 
as single anomalous diffraction using the iron K edge. Data were processed using XDS8, and 
three data sets were merged to increase anomalous signal redundancy. The data were used with 
AutoSol9 for experimental phasing and model building. Following model building and initial 
refinements in PHENIX,10 chain A of this model was used as a search model. The highest quality 
data set was determined in AIMLESS11 to have a high-resolution shell limit of 2.45 Å. Molecular 
replacement was performed using Phaser-MR12 with the merged data set model as the search 
model. The model was iteratively refined using PHENIX refine and COOT13 and validated with 
MolProbity. Crystallographic and model statistics are described in Supplementary table S3. 
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Table S3. Crystal data and refinement statistics for RmaNOD Q52V. 
Structure name 
Engineered carbene transferase 
RmaNOD Q52V, putative nitric oxide 
dioxygenase from Rhodothermus marinus 
PDB ID 6WK3 
Wavelength 1.74 Å 
Resolution range 43.65  - 2.45 (2.538  - 2.45) 
Space group C 1 2 1 
Unit cell 
a = 124.269, b = 102.472, c = 84.273 
α = 90, β = 98.529, γ = 90 
Total reflections 248224 (25486) 
Unique reflections 36943 (3600) 
Multiplicity 6.7 (7.1) 
Completeness (%) 95.98 (94.17) 
Mean I/sigma(I) 13.34 (1.53) 
Wilson B-factor 58.05 
R-merge 0.09393 (1.464) 
R-meas 0.1022 (1.581) 
R-pim 0.03949 (0.5911) 
CC1/2 0.997 (0.647) 
Reflections used in refinement 36927 (3600) 
Reflections used for R-free 1816 (177) 
R-work 0.2077 (0.2991) 
R-free 0.2467 (0.3343) 
CC(work) 0.966 (0.785) 
CC(free) 0.959 (0.723) 
Number of non-hydrogen atoms 4680 
  macromolecules 4481 
  Ligands 198 
  Solvent 1 
Protein residues 578 
RMS(bonds) 0.004 
RMS(angles) 0.74 
Ramachandran favored (%) 99.30 
Ramachandran allowed (%) 0.70 
Ramachandran outliers (%) 0.00 
Rotamer outliers (%) 0.00 
Clashscore 4.49 
Average B-factor 60.86 
  macromolecules 61.08 
  Ligands 55.85 
  Solvent 55.94 
Number of TLS groups 1 
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Small-Molecule Crystal Formation and Data Collection 
Small-molecule crystal formation 
A small sample (~1 mg) of 4 produced from RmaNOD THRAW preparative-scale reactions was 
recrystallized from slow evaporation of acetone to provide crystals suitable for X-ray diffraction.  
 
X-Ray refinement details 
Low-temperature diffraction data (- and -scans) were collected on a Bruker AXS D8 VENTURE 
KAPPA diffractometer coupled to a PHOTON II CPAD detector with either Mo-K radiation ( = 
0.71073 Å) from a fine-focus sealed X-ray tube. All diffractometer manipulations, including data 
collection integration, and scaling were carried out using the Bruker APEXII software.14 Absorption 
corrections were applied using SADABS. The structure was solved by intrinsic phasing using 
SHELXT15 and refined against F2 on all data by full-matrix least squares with SHELXL-201416 
using established refinement techniques.17 All non-hydrogen atoms were refined anisotropically. 
All hydrogen atoms were included into the model at geometrically calculated positions and refined 
using a riding model. The isotropic displacement parameters of all hydrogen atoms were fixed to 
1.2 times the U value of the atoms they are linked to (1.5 times for methyl groups). Absolute 
configuration was determined by anomalous dispersion.18 Graphical representation of the 
structure with 50% probability thermal ellipsoids was generated using Mercury visualization 
software. The crystal data and structure refinement for this compound (noted as D19046_b) is 
given in   
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Table S4. The atomic coordinate positions are provided as a separate supplemental file.  
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Table S4. Crystal data and structure refinement for D19046_b. 
Identification code d19046_b 
Empirical formula C12 H18 B2 F6 K2 O4 
Formula weight 440.08 
Temperature 100 K 
Wavelength 0.71073 Å 
Crystal system Monoclinic 
Space group P 1 21 1 
Unit cell dimensions 
a = 9.9422(8) Å, α = 90°. 
b = 6.0314(5) Å, β = 103.236(2)°. 
c = 15.4530(12) Å, γ = 90°. 
Volume 902.03(13) Å3 
Z 2 
Density (calculated) 1.620 Mg/m3 
Absorption coefficient 0.599 mm-1 
F(000) 448 
Crystal size 0.39 x 0.28 x 0.02 mm3 
Theta range for data collection 2.104 to 27.525°. 
Index ranges -12<=h<=12, -7<=k<=7, -20<=l<=20 
Reflections collected 30884 
Independent reflections 4145 [R(int) = 0.0306] 
Completeness to theta = 25.242° 99.9 % 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7456 and 0.6852 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4145 / 1 / 237 
Goodness-of-fit on F2 1.054 
Final R indices [I>2sigma(I)] R1 = 0.0215, wR2 = 0.0560 
R indices (all data) R1 = 0.0225, wR2 = 0.0565 
Absolute structure parameter 0.015(7) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.435 and -0.249 e.Å-3 
 
The crystal of 4 generated from cis-3 purified from a reaction with RmaNOD THRAW was solved 
as (1R, 2S). This configuration is in agreement with the absolute configuration assignment by 
analogy when comparing the enantiomer produced by RmaNOD Y32T Q52A and ApePgb AGW 
(based on ApePgb AGW’s enantioselective cyclopropanation of 1-octene and EDA).5  
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Figure S4. Small-molecule crystal structure of the BF3K-substituted cyclopropane product 4 
generated by the RmaNOD-THRAW-catalyzed reaction of 1 and 2. 
Compound Synthesis and Characterization 
 
Racemic standards of cis-3 and trans-3 were prepared according to a three-step procedure by 
Bull and coworkers.19  
 
Ethyl (trans)-2-(phenylthio)cyclopropane-1-carboxylate and ethyl (cis)-2-
(phenylthio)cyclopropane-1-carboxylate 
 
A round-bottom flask containing a racemic mixture of N,N'-bis(3,5-di-tert-butylsalicylidene)-1,2-
cyclohexanediaminocobalt(II) (0.043 equiv, 726 mg total, 363 mg of each enantiomer) was 
flushed with Ar for 15 minutes, and then 50 mL of degassed water were added (water was 
degassed by bubbling Ar gas through the liquid for 30 minutes). The ethyl diazoacetate (1.0 equiv, 
2.9 mL) and phenyl vinyl sulfide (1.5 equiv, 4.7 mL) were added via syringe, and the reaction was 
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stirred under a positive pressure of Ar (balloon) at 40 °C for 24 hours. Upon completion, the 
reaction was cooled to room temperature and 12 mL of isohexane was added. Air was bubbled 
through the reaction for 30 minutes to oxidize the Co catalyst. The crude mixture was then filtered 
through a pad of silica gel, which was subsequently washed with CH2Cl2. The solution was 
concentrated and purified by column chromatography (silica, 15:1 pentane:Et2O) to provide 2.05 
g of cis-S1 (33% yield) and 2.28 g of trans-S1 (37% yield). 
 
 
 
Each diastereomer of S1 was monooxidized with m-CPBA and subsequently converted to the 
boronic ester according to the following procedures. 
 
Ethyl (trans)-2-((S)-phenylsulfinyl)cyclopropane-1-carboxylate 
The cyclopropane trans-S1 (1.97 g) was added to a round-bottom flask, dissolved in 90 mL of 
CH2Cl2, and cooled to 0 °C. The m-CPBA (99%, 1.63 g) was added in three portions over 30 
minutes and then continued to stir for 2 hours at 0 °C. Aqueous KOH (3 M, 35 mL) was added, 
and the layers were separated. The aqueous layer was extracted with CH2Cl2 (5 x 35 mL). The 
combined organic layers were dried with MgSO4, filtered, and concentrated. The crude material 
was purified by column chromatography (silica, 1:2 hexane:Et2O) to provide 1.39 g of trans-S2 
(66% yield). 
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Ethyl (cis)-2-((S)-phenylsulfinyl)cyclopropane-1-carboxylate 
The cyclopropane cis-S1 (1.78 g) was added to a round-bottom flask, dissolved in 80 mL of 
CH2Cl2 and cooled to 0 °C. The m-CPBA (99%, 1.44 g) was added in three portions over 30 
minutes and then continued to stir for 2 hours at 0 °C. Aqueous KOH (3 M, 30 mL) was added, 
and the layers were separated. The aqueous layer was extracted with CH2Cl2 (5 x 30 mL). The 
combined organic layers were dried with MgSO4, filtered, and concentrated. The crude material 
was purified by column chromatography (silica, 1:2 hexane: diethyl ether) to provide 1.20 g of cis-
S2 (63% yield). 
 
Ethyl (cis)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclopropane-1-
carboxylate 
The cyclopropane trans-S2 (1.29 g) was added to a round-bottom flask and dissolved in 54 mL 
of THF. The reaction was cooled to –78 °C, and then the iPrMgCl (2 M, 4.4 mL) was added 
dropwise. The reaction continued to stir for 10 minutes before the addition of 2-isopropoxy-
4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2.2 mL). The reaction was warmed to 0 °C and 
continued to stir for 6 hours before being warmed to room temperature. Methanol (15 mL) was 
added to quench the reaction and stirred for 5 minutes. Then 150 mL of diethyl ether were added, 
the mixture was filtered and concentrated. The crude mixture was purified by column 
chromatography (florisil, 10% to 50% diethyl ether : hexane) to provide 480 mg of trans-3 (37% 
yield). 1H NMR (400 MHz, chloroform-d) δ 4.19 – 3.98 (m, 2H), 1.83 – 1.73 (m, 1H), 1.26 – 1.21 
(m, 12H), 1.12 – 1.04 (m, 1H), 1.04 – 0.96 (m, 1H), 0.43 – 0.31 (m, 1H). 13C NMR (101 MHz, 
CDCl3) δ 174.5, 83.6, 60.6, 25.0, 25.0, 17.8, 14.4, 11.3. 11B NMR (128 MHz, CDCl3) δ 32.1. 
 
S26 
 
Ethyl (cis)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclopropane-1-
carboxylate 
The cyclopropane cis-S2 (1.10 g) was added to a round-bottom flask and dissolved in 46 mL of 
THF. The reaction was cooled to –78 °C, and then the iPrMgCl (2 M, 3.5 mL) was added dropwise. 
The reaction continued to stir for 10 minutes before the addition of 2-isopropoxy-4,4,5,5-
tetramethyl-1,3,2-dioxaborolane (1.9 mL). The reaction was warmed to 0 °C and continued to stir 
for 6 hours before being warmed to room temperature. Methanol (15 mL) was added to quench 
the reaction and stirred for 5 minutes. Then 150 mL of diethyl ether were added, the mixture was 
filtered and concentrated. The crude mixture was purified by column chromatography (florisil, 10% 
to 50% diethyl ether: hexane) to provide 440 mg of cis-3 (39% yield). 1H NMR (400 MHz, 
chloroform-d) δ 4.18 – 4.04 (m, 2H), 1.79 – 1.69 (m, 1H), 1.21 (d, J = 1.7 Hz, 12H), 1.02 – 0.92 
(m, 1H), 0.62 – 0.51 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 174.3, 83.5, 60.5, 24.8, 24.7, 18.6, 
14.3, 13.0. 11B NMR (128 MHz, CDCl3) δ 32.58. 
 
Ethyl (1R,2S)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclopropane-1-
carboxylate (enzymatic) 
 
Whole E. coli cells were grown fresh as described above (Medium- and large-scale protein 
expression); two 1-L cultures in 2.8-L non-baffled flasks were grown for RmaNOD THRAW. The 
cells were resuspended in 1X M9-N buffer (OD600 = 30, 664 mL) and transferred into a 1-L round-
bottom flask with a stir bar. The round-bottom flask was sealed with a septum and attached to a 
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Schlenk line; three cycles of Argon purging and vacuum evacuation were used to remove oxygen 
from the reaction flask. The mixture remained under argon flow throughout the entire reaction. 
Substrate (1) (neat stock, 7.5 mL, 60 mM final concentration) was added via syringe. EDA (2) 
(10.41 mL diluted in 35.9 mL ethanol cosolvent, 120 mM final concentration) was added over 2 
hours via syringe pump slow addition. The reaction continued to stir overnight (16 hours) at room 
temperature. The reactions were then extracted three times with 1:1 hexane:ethyl acetate. The 
organic fractions were concentrated in vacuo and used in the subsequent protection step without 
purification. To the crude mixture of 3 and the deprotected cyclopropylboronic acid (6) were added 
pinacol (1.18 g), anhydrous magnesium sulfate (15 g), and anhydrous diethyl ether (100 mL). The 
reaction flask was sealed with a rubber septum and stirred for 2 hours at room temperature. After 
2 hours, an aliquot was analyzed by 1H NMR spectroscopy to ensure complete consumption of 6. 
The reaction was filtered over a plug of anhydrous MgSO4, concentrated, and purified by 
distillation.  
The crude mixture was purified via fractional distillation using a short path distillation setup 
attached to a small Vigreux column under reduced pressure. The residual alkene starting material 
was isolated at 10 torr and 40 °C to obtain 820 mg of the reagent as a colorless oil. The Vigreux 
column was then removed and a mixture of the desired product 3, diethyl fumarate, and diethyl 
maleate were co-distilled at 5 torr and 70–100 °C. The obtained mixture was transferred to a 
round-bottom flask and vigorously stirred while heated under vacuum (40 °C at 1 torr for 24 hours, 
then 45 °C at 1 torr for 24 hours, then 50 °C at 1 torr for 3.5 hours) to remove the undesired diethyl 
fumarate and diethyl maleate side products. Product 3 was isolated as a colorless oil (3.7 g, 95% 
purity, 36% yield, 41% yield BRSM). 
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Ethyl (1R,2S)-2-(trifluoro-l4-boranyl)cyclopropane-1-carboxylate, potassium salt 
((1R, 2S)-4)) 
 
To a dram vial equipped with a magnetic stir bar were added 3 (50 mg, 0.208 mmol, 1 equiv) and 
1 mL of ethanol. A solution of KHF2 (78 mg, 1 mmol, 5 equiv) in 0.22 mL of water was added to 
the vial, then sealed with a screw cap, and stirred overnight at room temperature. Upon 
completion, the solvent was removed in vacuo and the BF3K salt was extracted with acetone (3 x 
4 mL). The combined organic layers were filtered through a plug of cotton and concentrated to 
provide 35 mg of the desired cyclopropyl BF3K salt (76% yield). A small sample (~1 mg) was 
recrystallized from slow evaporation of acetone to provide crystals suitable for X-ray diffraction. 
1H NMR (400 MHz, DMSO-d6) δ 3.92 (qd, J = 7.1, 1.2 Hz, 2H), 1.32 – 1.22 (m, 1H), 1.12 (t, J = 
7.1 Hz, 3H), 0.75 (ddd, J = 8.8, 4.9, 2.5 Hz, 1H), 0.56 (dddt, J = 10.8, 8.2, 2.4, 1.1 Hz, 1H), -0.13 
(dddt, J = 14.7, 10.3, 8.7, 4.3 Hz, 1H). 13C NMR (101 MHz, DMSO) δ 174.9, 59.1, 40.6, 40.4, 40.2, 
40.0, 39.8, 39.6, 39.3, 17.3, 17.3, 17.3, 17.3, 14.7, 10.3, 10.3, 10.2, 10.2.  11B NMR (128 MHz, 
DMSO-d6) δ 3.43, 3.00. 19F NMR (282 MHz, DMSO-d6) δ -135.1, -135.2. 
 
Suzuki-Miyaura cross-coupling with 4 
 
In a glovebox under an inert atmosphere, 4 (4.4 mg, 0.02 mmol, 1 equiv) was dissolved in 110 
 L of a mixture of 10:1 toluene:degassed water in a half dram vial equipped with a magnetic stir 
bar. The 4-bromoanisole (5.6 mg, 1.5 equiv), Pd(OAc)2 (0.09 mg, 0.02 equiv), n-BuPAd2 (0.22 
mg, 0.03 equiv), and Cs2CO3 (17.6 mg, 2.7 equivalents) were added sequentially. The vial was 
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sealed with a Teflon cap, wrapped with electrical tape, and stirred at 100 °C for 20 hours. The 
reaction was cooled to room temperature, loaded onto a packed silica column, and analyzed by 
1H NMR against an internal standard to determine the product yield. 
 
General procedure: Suzuki-Miyaura cross-coupling with cis-3 
 
In a glovebox under an inert atmosphere, cis-3 (48 mg, 0.2 mmol, 1 equiv), aryl bromide (1.5 
equiv), Pd(OAc)2 (2.2 mg, 0.05 equiv), n-BuPAd2 (5 mg, 0.07 equiv), Cs2CO3 (3.0 equiv), and 
toluene (2 mL) were sequentially added to a 2-dram vial equipped with a magnetic stir bar. The 
vial was sealed with a Teflon cap, wrapped with electrical tape, and stirred at 100 °C for 36 hours. 
The reaction was cooled to room temperature, loaded onto a packed silica column, and purified 
by column chromatography to afford the desired product. 
 
Ethyl (1R,2S)-2-(4-methoxyphenyl)cyclopropane-1-carboxylate (5a) 
Prepared from (1R,2S)-3 (48 mg, 1.0 equiv, 0.2 mmol) and 1-bromo-4-
methoxybenzene (56 mg, 1.5 equiv, 0.3 mmol). The crude residue was 
purified by column chromatography (silica, 10% Et2O/hexanes) to yield 40.4 mg of 5a (92% yield). 
The product was analyzed by chiral SFC and no minor enantiomer peak was detected, confirming 
the product is formed in >99% ee. This is a known compound, and the spectroscopic data are in 
agreement with the literature.6 Chiral SFC: (OJ-H, 2.5 mL/min, 5% IPA in CO2,  = 254 nm): tR 
(major) = 3.9 min, tR (minor) = 5.5 min. 1H NMR (400 MHz, chloroform-d) δ 7.21 – 7.15 (m, 2H), 
6.80 (dt, J = 8.9, 2.5 Hz, 2H), 3.89 (q, J = 7.1 Hz, 2H), 3.77 (s, 3H), 2.52 (q, J = 8.7, 8.0 Hz, 1H), 
2.03 (ddd, J = 9.2, 7.8, 5.6 Hz, 1H), 1.70 – 1.61 (m, 1H), 1.30 (ddd, J = 8.7, 7.8, 5.0 Hz, 1H), 1.02 
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(t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 171.2, 158.4, 130.4, 128.7, 113.4, 60.3, 55.3, 
25.0, 21.8, 14.2, 11.4. HRMS (EI+, m/z): calculated for C13H16O3 [M]+: 220.1100, found 220.1095. 
 
Ethyl (1R,2S)-2-(3,4-difluorophenyl)cyclopropane-1-carboxylate (5b) 
Prepared from (1R,2S)-3 (48 mg, 1.0 equiv, 0.2 mmol) and 4-bromo-1,2-
difluorobenzene (58 mg, 1.5 equiv, 0.3 mmol). The crude residue was purified 
by column chromatography (silica, 10% Et2O/hexanes) to yield 29.7 mg of 5b (66% yield). The 
product was analyzed by chiral SFC and no minor enantiomer peak was detected, confirming the 
product is formed in >99% ee. Chiral SFC: (OJ-H, 2.5 mL/min, 0% IPA in CO2,  = 210 nm): tR 
(major) = 2.9 min, tR (minor) = 3.4 min. 1H NMR (400 MHz, chloroform-d) δ 7.13 – 6.93 (m, 3H), 
3.92 (q, J = 7.1 Hz, 2H), 2.56 – 2.45 (m, 1H), 2.07 (ddd, J = 9.3, 7.9, 5.7 Hz, 1H), 1.63 (ddd, J = 
7.4, 5.6, 5.2 Hz, 1H), 1.34 (ddd, J = 8.7, 7.9, 5.3 Hz, 1H), 1.05 (t, J = 7.1 Hz, 3H). 13C NMR (101 
MHz, CDCl3) δ 170.8, 151.2, 151.1, 150.7, 150.5, 148.7, 148.6, 148.2, 148.1, 133.9, 133.8, 133.8, 
133.8, 133.8, 125.5, 125.4, 125.4, 125.4, 118.4, 118.3, 116.8, 116.6, 60.6, 24.7, 24.7, 21.9, 14.2, 
11.7. 19F NMR (282 MHz, CDCl3) δ -138.7 (m), -140.7 (m). HRMS (EI+, m/z): calculated for 
C12H12F2O2 [M]+: 226.0805, measured 226.0805. 
 
Ethyl (1R,2S)-2-(anthracen-9-yl)cyclopropane-1-carboxylate (5c) 
Prepared from (1R,2S)-3 (48 mg, 1.0 equiv, 0.2 mmol) and 9-
bromoanthracene (77 mg, 1.5 equiv, 0.3 mmol). The crude residue was 
purified by column chromatography (silica, 5-15% Et2O/hexanes) to yield 
25.5 mg of 5c (44% yield). The product was analyzed by chiral SFC and no minor enantiomer 
peak was detected, confirming the product is formed in >99% ee. Chiral SFC: (OJ-H, 2.5 mL/min, 
15% IPA in CO2,  = 254 nm): tR (major) = 7.3 min, tR (minor) = 7.9 min. 1H NMR (400 MHz, 
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Chloroform-d) δ 8.63 (d, J = 8.9 Hz, 1H), 8.50 (d, J = 8.7 Hz, 1H), 8.36 (s, 1H), 7.98 (t, J = 8.6 Hz, 
2H), 7.51 – 7.42 (m, 4H), 3.55 – 3.34 (m, 2H), 3.09 (q, J = 8.3, 7.9 Hz, 1H), 2.57 (td, J = 8.3, 5.6 
Hz, 1H), 2.01 (ddd, J = 8.8, 8.1, 4.6 Hz, 1H), 1.82 (ddd, J = 7.8, 5.6, 4.7 Hz, 1H), 0.54 (t, J = 7.1 
Hz, 3H). 13C NMR (126 MHz, CDCl3):  171.8, 131.9, 131.8, 131.2, 129.7, 129.4, 129.0, 127.0, 
125.6, 125.5, 125.3, 125.1, 125.0, 124.8, 60.1, 22.5, 20.9, 16.7, 13.6. 
 
Ethyl (1R,2S)-2-(6-chloropyridin-3-yl)cyclopropane-1-carboxylate (5d) 
Prepared from (1R,2S)-3 (48 mg, 1.0 equiv, 0.2 mmol) and 5-bromo-2-
chloropyridine (58 mg, 1.5 equiv, 0.3 mmol). The crude residue was purified 
by column chromatography (silica, 5-40% Et2O/hexanes) to yield 15 mg of 5d (33% yield) as a 
colorless oil. The product was analyzed by chiral SFC, confirming the product is formed in >99% 
ee. Chiral SFC: (OJ-H, 2.5 mL/min, 10% IPA in CO2,  = 254 nm): tR (major) = 2.3 min, tR (minor) 
= 2.6 min. 
1H NMR (400 MHz, chloroform-d) δ 8.30 (dt, J = 2.5, 0.7 Hz, 1H), 7.53 (ddd, J = 8.2, 2.5, 0.7 Hz, 
1H), 7.25 – 7.19 (m, 1H), 3.94 (qt, J = 7.1, 3.6 Hz, 2H), 2.48 (q, 1H), 2.14 (ddd, J = 9.0, 7.9, 5.7 
Hz, 1H), 1.67 (dt, J = 7.5, 5.5 Hz, 1H), 1.42 (ddd, J = 8.7, 8.0, 5.2 Hz, 1H), 1.06 (t, J = 7.1 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ 170.6, 150.9, 149.8, 139.5, 131.5, 123.5, 60.8, 22.2, 21.8, 
14.3, 11.4. HRMS (FAB, m/z): calculated for C11H12ClNO2 [M]+: 225.0557, measured 225.0706. 
 
Suzuki-Miyaura cross-coupling reactions with trans-3 
 
In a glovebox under an inert atmosphere, trans-3 (4.8 mg, 0.02 mmol, 1 equiv), aryl bromide (1.5 
equiv), Pd(OAc)2 (0.22 mg, 0.005 equiv), n-BuPAd2 (0.5–0.8 mg, 0.07–0.11 equiv), Cs2CO3 (3.0 
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equiv), and toluene (0.2 mL) were sequentially added to a 1/2-dram vial equipped with a magnetic 
stir bar. The vial was sealed with a Teflon cap, wrapped with electrical tape, and stirred at 100 °C 
for 24 hours. The reaction was cooled to room temperature, flushed through a pipet over a short 
pad of silica gel, and concentrated in vacuo. The crude reaction was dissolved in CDCl3 and 
analyzed by NMR versus an added standard (2,3,5,6-tetrachloronitrobenzene) to obtain an NMR 
yield of the product.  
 
Ethyl trans-2-(4-methoxyphenyl)cyclopropane-1-carboxylate 
Prepared from trans-3 (4.8 mg, 1.0 equiv, 0.02 mmol) and 1-bromo-4-
methoxybenzene (5.6 mg, 1.5 equiv, 0.03 mmol). The crude residue was 
analyzed by NMR spectroscopy against an internal standard (2.0 mg of 2,3,5,6-
tetrachloronitrobenzene, singlet at 7.73 ppm) to afford the reaction yield (56%). 1H NMR (500 
MHz, Chloroform-d) δ 7.06 – 7.01 (m, 2H), 6.84 – 6.80 (m, 2H), 4.17 (q, J = 7.1 Hz, 2H), 3.79 (s, 
5H), 2.49 (ddd, J = 9.2, 6.5, 4.2 Hz, 1H), 1.83 (ddd, J = 8.4, 5.2, 4.1 Hz, 1H), 1.56 (ddd, J = 9.4, 
5.2, 4.4 Hz, 1H), 1.29 (t, J = 7.1 Hz, 3H), 1.28 – 1.24 (m, 1H). 
 
Ethyl trans-2-(3,4-difluorophenyl)cyclopropane-1-carboxylate 
Prepared from trans-3 (4.8 mg, 1.0 equiv, 0.02 mmol) and 4-bromo-1,2-
difluorobenzene (5.8 mg, 1.5 equiv, 0.03 mmol). The crude residue was 
analyzed by NMR spectroscopy against an internal standard (3.5 mg of 2,3,5,6-
tetrachloronitrobenzene, singlet at 7.73 ppm) to afford the reaction yield (61%). 1H NMR (500 
MHz, Chloroform-d) δ 7.11 (dt, J = 10.2, 8.3 Hz, 1H), 6.94 (ddd, J = 11.4, 7.5, 2.3 Hz, 1H), 6.89 
(ddt, J = 8.2, 3.9, 1.8 Hz, 1H), 4.23 (qd, J = 7.2, 0.8 Hz, 2H), 2.53 (ddd, J = 9.3, 6.4, 4.1 Hz, 1H), 
1.91 (ddd, J = 8.5, 5.3, 4.2 Hz, 1H), 1.70 – 1.62 (m, 1H), 1.37 – 1.33 (m, 3H), 1.32 – 1.29 (m, 1H).  
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Chromatographic Data 
 
Compound separation conditions 
Table S5. Achiral separation conditions for compound 3. 
Compound Instrument; 
column 
Method program Retention times 
3 GC-FID; 
HP-5  
90 °C isothermal 1 minute 
15 °C/min to 110 °C 
60 °C/min to 280 °C isothermal 
1 minute  
Internal standard: 2.9 minutes 
Cis-3: 4.6 min 
Trans-3: 4.7 min 
3 GC-MS; 
HP-5ms UI 
90 °C isothermal 1 minute 
75 °C/min to 325 °C isothermal 
1.5 minutes 
Internal standard: 2.3 min 
Cis-3: 3.55 min 
Trans-3: 3.76 min 
 
 
Table S6. Chiral separation conditions. Due to the worse separation conditions for trans-3 
enantiomers, a separate method was prepared when only cis-3 enantioselectivity was to be 
measured. 
Compound Instrument; column Method program Retention times 
Cis-3 GC-MS; CP-Chirasil 
Dex CB (25 m, 0.25 
mm ID, 0.25 µm film 
thickness) 
80 °C isothermal 2 minutes 
10 °C/min to 130 °C, 
isothermal 15 minutes 
Cis minor: 14.3 min, 
major: 14.8 min 
(trans unresolved): 19.0 
min  
Trans-3  GC-MS; CP-Chirasil 
Dex CB (25 m, 0.25 
mm ID, 0.25 µm film 
thickness) 
90 °C isothermal 180 
minutes 
Cis major (1R, 2S): 87.4 
min, minor: 98.9 min 
Trans major: 172.8 min, 
minor: 177.8 min 
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Calibration curves for analytical-scale assays 
 
Figure S5. GC-MS calibration curve for cis-3. 
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Figure S6. GC-MS calibration curve for trans-3. 
 
Representative chromatographic traces 
Chromatographic separation conditions for each compound are reported in the Compound 
separation conditions section above. The chiral SFC method information is detailed in compound 
synthesis and characterization for the title compound. 
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Figure S7. Chiral GC-MS trace of racemic authentic standard 3 on method to determine cis-3 
enantioselectivity and RmaNOD THRAW catalyzed production of 3. 
 
 
Figure S8. Chiral GC-MS trace of racemic authentic standard 3 on method to determine trans-3 
enantioselectivity and RmaNOD WAIHNM catalyzed production of 3. 
 
S37 
 
 
 
Figure S9. Chiral SFC trace of rac-5a. 
 
 
 
Figure S10. Chiral SFC trace of chemoenzymatic product 5a. The enantioenriched sample shows 
no minor stereoisomer peak. 
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Figure S11. Chiral SFC trace of rac-5b.  
 
 
Figure S12. Chiral SFC trace of chemoenzymatic product 5b. The enantioenriched sample shows 
no minor stereoisomer peak. 
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Figure S13. Chiral SFC trace of rac-5c. 
 
 
 
Figure S14. Chiral SFC trace of chemoenzymatic product 5c. The enantioenriched sample shows 
only trace of the minor stereoisomer peak. 
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Figure S15. Chiral SFC trace of rac-5d.  
 
 
Figure S16. Chiral SFC trace of chemoenzymatic product 5d. The enantioenriched sample shows 
only trace of the minor stereoisomer peak. 
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DNA and Amino-Acid Sequences 
 
The DNA and amino-acid sequences for variants used in this work, as well as primer sequences 
for mutagenesis and cloning, are also provided as a separate supplemental Excel file. 
Nucleotide sequences of proteins of interest 
Table S7. Nucleotide sequences of proteins of interest. 
Protein 
name 
Nucleotide sequence 
RmaNOD 
wild type 
(WT) 
ATGGCGCCGACCCTGTCGGAACAGACCCGTCAGTTGGTACGTGCGTCTG
TGCCTGCACTGCAGAAACACTCAGTCGCTATTAGCGCCACGATGTATCGG
CTGCTTTTCGAACGGTATCCCGAAACGCGGAGCTTGTTTGAACTTCCTGA
GAGACAGATACACAAGCTTGCGTCGGCCCTGTTGGCCTACGCCCGTAGT
ATCGACAACCCATCGGCGTTACAGGCGGCCATCCGCCGCATGGTGCTTT
CCCACGCACGCGCAGGAGTGCAGGCCGTCCATTATCCGCTGGTTTGGGA
ATGTTTGAGAGACGCTATAAAAGAAGTCCTGGGCCCGGATGCCACCGAG
ACCCTTCTGCAGGCGTGGAAGGAAGCCTATGATTTTTTAGCTCATTTACTG
TCTACCAAGGAAGCGCAAGTCTACGCTGTGTTAGCTGAACTCGAGCATCA
CCATCACCATCACTGA 
RmaNOD 
Q52V 
ATGGCGCCGACCCTGTCGGAACAGACCCGTCAGTTGGTACGTGCGTCTG
TGCCTGCACTGCAGAAACACTCAGTCGCTATTAGCGCCACGATGTATCGG
CTGCTTTTCGAACGGTATCCCGAAACGCGGAGCTTGTTTGAACTTCCTGA
GAGAGTTATACACAAGCTTGCGTCGGCCCTGTTGGCCTACGCCCGTAGTA
TCGACAACCCATCGGCGTTACAGGCGGCCATCCGCCGCATGGTGCTTTC
CCACGCACGCGCAGGAGTGCAGGCCGTCCATTATCCGCTGGTTTGGGAA
TGTTTGAGAGACGCTATAAAAGAAGTCCTGGGCCCGGATGCCACCGAGA
CCCTTCTGCAGGCGTGGAAGGAAGCCTATGATTTTTTAGCTCATTTACTGT
CTACCAAGGAAGCGCAAGTCTACGCTGTGTTAGCTGAACTCGAGCACCAC
CACCACCACCACTGA 
RmaNOD 
Q52V with 
cleavable N-
terminal His 
– SUMO 
construct 
(underline 
denotes 
cleaved 
region) 
ATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGC
GCGGCAGCCATATGGCTAGCATGTCGGACTCAGAAGTCAATCAAGAAGC
TAAGCCAGAGGTCAAGCCAGAAGTCAAGCCTGAGACTCACATCAATTTAA
AGGTGTCCGATGGATCTTCAGAGATCTTCTTCAAGATCAAAAAGACCACT
CCTTTAAGAAGGCTGATGGAAGCGTTCGCTAAAAGACAGGGTAAGGAAAT
GGACTCCTTAAGATTCTTGTACGACGGTATTAGAATTCAAGCTGATCAGAC
CCCTGAAGATTTGGACATGGAGGATAACGATATTATTGAGGCTCACAGAG
AACAGATTGGTGGATCCATGGCGCCGACCCTGTCGGAACAGACCCGTCA
GTTGGTACGTGCGTCTGTGCCTGCACTGCAGAAACACTCAGTCGCTATTA
GCGCCACGATGTATCGGCTGCTTTTCGAACGGTATCCCGAAACGCGGAG
CTTGTTTGAACTTCCTGAGAGAGTTATACACAAGCTTGCGTCGGCCCTGT
TGGCCTACGCCCGTAGTATCGACAACCCATCGGCGTTACAGGCGGCCAT
CCGCCGCATGGTGCTTTCCCACGCACGCGCAGGAGTGCAGGCCGTCCAT
TATCCGCTGGTTTGGGAATGTTTGAGAGACGCTATAAAAGAAGTCCTGGG
CCCGGATGCCACCGAGACCCTTCTGCAGGCGTGGAAGGAAGCCTATGAT
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TTTTTAGCTCATTTACTGTCTACCAAGGAAGCGCAAGTCTACGCTGTGTTA
GCTGAATAATGA 
RmaNOD 
Q52A 
ATGGCGCCGACCCTGTCGGAACAGACCCGTCAGTTGGTACGTGCGTCTG
TGCCTGCACTGCAGAAACACTCAGTCGCTATTAGCGCCACGATGTATCGG
CTGCTTTTCGAACGGTATCCCGAAACGCGGAGCTTGTTTGAACTTCCTGA
GAGAGCGATACACAAGCTTGCGTCGGCCCTGTTGGCCTACGCCCGTAGT
ATCGACAACCCATCGGCGTTACAGGCGGCCATCCGCCGCATGGTGCTTT
CCCACGCACGCGCAGGAGTGCAGGCCGTCCATTATCCGCTGGTTTGGGA
ATGTTTGAGAGACGCTATAAAAGAAGTCCTGGGCCCGGATGCCACCGAG
ACCCTTCTGCAGGCGTGGAAGGAAGCCTATGATTTTTTAGCTCATTTACTG
TCTACCAAGGAAGCGCAAGTCTACGCTGTGTTAGCTGAACTCGAGCACCA
CCACCACCACCACTGA 
RmaNOD 
Y32T Q52A  
ATGGCGCCGACCCTGTCGGAACAGACCCGTCAGTTGGTACGTGCGTCTG
TGCCTGCACTGCAGAAACACTCAGTCGCTATTAGCGCCACGATGACGCG
GCTGCTTTTCGAACGGTATCCCGAAACGCGGAGCTTGTTTGAACTTCCTG
AGAGAGCGATACACAAGCTTGCGTCGGCCCTGTTGGCCTACGCCCGTAG
TATCGACAACCCATCGGCGTTACAGGCGGCCATCCGCCGCATGGTGCTT
TCCCACGCACGCGCAGGAGTGCAGGCCGTCCATTATCCGCTGGTTTGGG
AATGTTTGAGAGACGCTATAAAAGAAGTCCTGGGCCCGGATGCCACCGA
GACCCTTCTGCAGGCGTGGAAGGAAGCCTATGATTTTTTAGCTCATTTACT
GTCTACCAAGGAAGCGCAAGTCTACGCTGTGTTAGCTGAACTCGAGCACC
ACCACCACCACCACTGA 
RmaNOD 
Y32T Y39H 
L48R Q52A 
R79W 
(“THRAW”)  
ATGGCGCCGACCCTGTCGGAACAGACCCGTCAGTTGGTACGTGCGTCTG
TGCCTGCACTGCAGAAACACTCAGTCGCTATTAGCGCCACGATGACGCG
GCTGCTTTTCGAACGGCATCCCGAAACGCGGAGCTTGTTTGAACGTCCTG
AGAGAGCGATACACAAGCTTGCGTCGGCCCTGTTGGCCTACGCCCGTAG
TATCGACAACCCATCGGCGTTACAGGCGGCCATCCGCTGGATGGTGCTT
TCCCACGCACGCGCAGGAGTGCAGGCCGTCCATTATCCGCTGGTTTGGG
AATGTTTGAGAGACGCTATAAAAGAAGTCCTGGGCCCGGATGCCACCGA
GACCCTTCTGCAGGCGTGGAAGGAAGCCTATGATTTTTTAGCTCATTTACT
GTCTACCAAGGAAGCGCAAGTCTACGCTGTGTTAGCTGAACTCGAGCACC
ACCACCACCACCACTGA 
RmaNOD 
Q52A 
L101N 
ATGGCGCCGACCCTGTCGGAACAGACCCGTCAGTTGGTACGTGCGTCTG
TGCCTGCACTGCAGAAACACTCAGTCGCTATTAGCGCCACGATGTATCGG
CTGCTTTTCGAACGGTATCCCGAAACGCGGAGCTTGTTTGAACTTCCTGA
GAGAGCGATACACAAGCTTGCGTCGGCCCTGTTGGCCTACGCCCGTAGT
ATCGACAACCCATCGGCGTTACAGGCGGCCATCCGCCGCATGGTGCTTT
CCCACGCACGCGCAGGAGTGCAGGCCGTCCATTATCCGCTGGTTTGGGA
ATGTAATAGAGACGCTATAAAAGAAGTCCTGGGCCCGGATGCCACCGAG
ACCCTTCTGCAGGCGTGGAAGGAAGCCTATGATTTTTTAGCTCATTTACTG
TCTACCAAGGAAGCGCAAGTCTACGCTGTGTTAGCTGAACTCGAGCACCA
CCACCACCACCACTGA 
RmaNOD 
Q52A 60H 
L101N 
ATGGCGCCGACCCTGTCGGAACAGACCCGTCAGTTGGTACGTGCGTCTG
TGCCTGCACTGCAGAAACACTCAGTCGCTATTAGCGCCACGATGTATCGG
CTGCTTTTCGAACGGTATCCCGAAACGCGGAGCTTGTTTGAACTTCCTGA
GAGAGCGATACACAAGCTTGCGTCGGCCCATTTGGCCTACGCCCGTAGT
ATCGACAACCCATCGGCGTTACAGGCGGCCATCCGCCGCATGGTGCTTT
CCCACGCACGCGCAGGAGTGCAGGCCGTCCATTATCCGCTGGTTTGGGA
ATGTAATAGAGACGCTATAAAAGAAGTCCTGGGCCCGGATGCCACCGAG
ACCCTTCTGCAGGCGTGGAAGGAAGCCTATGATTTTTTAGCTCATTTACTG
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TCTACCAAGGAAGCGCAAGTCTACGCTGTGTTAGCTGAACTCGAGCACCA
CCACCACCACCACTGA 
RmaNOD 
Q52A 60H 
L101N 
I105M 
ATGGCGCCGACCCTGTCGGAACAGACCCGTCAGTTGGTACGTGCGTCTG
TGCCTGCACTGCAGAAACACTCAGTCGCTATTAGCGCCACGATGTATCGG
CTGCTTTTCGAACGGTATCCCGAAACGCGGAGCTTGTTTGAACTTCCTGA
GAGAGCGATACACAAGCTTGCGTCGGCCCATTTGGCCTACGCCCGTAGT
ATCGACAACCCATCGGCGTTACAGGCGGCCATCCGCCGCATGGTGCTTT
CCCACGCACGCGCAGGAGTGCAGGCCGTCCATTATCCGCTGGTTTGGGA
ATGTAATAGAGACGCTATGAAAGAAGTCCTGGGCCCGGATGCCACCGAG
ACCCTTCTGCAGGCGTGGAAGGAAGCCTATGATTTTTTAGCTCATTTACTG
TCTACCAAGGAAGCGCAAGTCTACGCTGTGTTAGCTGAACTCGAGCACCA
CCACCACCACCACTGA 
RmaNOD 
L20W Q52A 
L56I 60H 
L101N 
I105M 
(WAIHNM) 
ATGGCGCCGACCCTGTCGGAACAGACCCGTCAGTTGGTACGTGCGTCTG
TGCCTGCATGGCAGAAACACTCAGTCGCTATTAGCGCCACGATGTATCGG
CTGCTTTTCGAACGGTATCCCGAAACGCGGAGCTTGTTTGAACTTCCTGA
GAGAGCGATACACAAGATTGCGTCGGCCCATTTGGCCTACGCCCGTAGT
ATCGACAACCCATCGGCGTTACAGGCGGCCATCCGCCGCATGGTGCTTT
CCCACGCACGCGCAGGAGTGCAGGCCGTCCATTATCCGCTGGTTTGGGA
ATGTAATAGAGACGCTATGAAAGAAGTCCTGGGCCCGGATGCCACCGAG
ACCCTTCTGCAGGCGTGGAAGGAAGCCTATGATTTTTTAGCTCATTTACTG
TCTACCAAGGAAGCGCAAGTCTACGCTGTGTTAGCTGAACTCGAGCACCA
CCACCACCACCACTGA 
 
Amino-acid sequences of proteins of interest. 
Table S8. Amino-acid sequences of proteins of interest. 
Protein name Amino-acid sequence 
RmaNOD wild type 
(WT) 
MAPTLSEQTRQLVRASVPALQKHSVAISATMYRLLFERYPETRSL
FELPERQIHKLASALLAYARSIDNPSALQAAIRRMVLSHARAGVQA
VHYPLVWECLRDAIKEVLGPDATETLLQAWKEAYDFLAHLLSTKE
AQVYAVLAELEHHHHHH* 
RmaNOD Q52V MAPTLSEQTRQLVRASVPALQKHSVAISATMYRLLFERYPETRSL
FELPERVIHKLASALLAYARSIDNPSALQAAIRRMVLSHARAGVQA
VHYPLVWECLRDAIKEVLGPDATETLLQAWKEAYDFLAHLLSTKE
AQVYAVLAELEHHHHHH* 
RmaNOD Q52V with 
cleavable N-terminal 
His – SUMO construct 
(underline denotes 
cleaved region) 
MGSSHHHHHHSSGLVPRGSHMASMSDSEVNQEAKPEVKPEVKP
ETHINLKVSDGSSEIFFKIKKTTPLRRLMEAFAKRQGKEMDSLRFL
YDGIRIQADQTPEDLDMEDNDIIEAHREQIGGSMAPTLSEQTRQLV
RASVPALQKHSVAISATMYRLLFERYPETRSLFELPERVIHKLASA
LLAYARSIDNPSALQAAIRRMVLSHARAGVQAVHYPLVWECLRDA
IKEVLGPDATETLLQAWKEAYDFLAHLLSTKEAQVYAVLAE** 
RmaNOD Q52A MAPTLSEQTRQLVRASVPALQKHSVAISATMYRLLFERYPETRSL
FELPERAIHKLASALLAYARSIDNPSALQAAIRRMVLSHARAGVQA
VHYPLVWECLRDAIKEVLGPDATETLLQAWKEAYDFLAHLLSTKE
AQVYAVLAELEHHHHHH* 
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RmaNOD Y32T Q52A  MAPTLSEQTRQLVRASVPALQKHSVAISATMTRLLFERYPETRSL
FELPERAIHKLASALLAYARSIDNPSALQAAIRRMVLSHARAGVQA
VHYPLVWECLRDAIKEVLGPDATETLLQAWKEAYDFLAHLLSTKE
AQVYAVLAELEHHHHHH* 
RmaNOD Y32T Y39H 
L48R Q52A R79W 
(“THRAW”)  
MAPTLSEQTRQLVRASVPALQKHSVAISATMTRLLFERHPETRSL
FERPERAIHKLASALLAYARSIDNPSALQAAIRWMVLSHARAGVQ
AVHYPLVWECLRDAIKEVLGPDATETLLQAWKEAYDFLAHLLSTK
EAQVYAVLAELEHHHHHH* 
RmaNOD Q52A L101N MAPTLSEQTRQLVRASVPALQKHSVAISATMYRLLFERYPETRSL
FELPERAIHKLASALLAYARSIDNPSALQAAIRRMVLSHARAGVQA
VHYPLVWECNRDAIKEVLGPDATETLLQAWKEAYDFLAHLLSTKE
AQVYAVLAELEHHHHHH* 
RmaNOD Q52A 60H 
L101N 
MAPTLSEQTRQLVRASVPALQKHSVAISATMYRLLFERYPETRSL
FELPERAIHKLASAHLAYARSIDNPSALQAAIRRMVLSHARAGVQA
VHYPLVWECNRDAIKEVLGPDATETLLQAWKEAYDFLAHLLSTKE
AQVYAVLAELEHHHHHH* 
RmaNOD Q52A 60H 
L101N I105M 
MAPTLSEQTRQLVRASVPALQKHSVAISATMYRLLFERYPETRSL
FELPERAIHKLASAHLAYARSIDNPSALQAAIRRMVLSHARAGVQA
VHYPLVWECNRDAMKEVLGPDATETLLQAWKEAYDFLAHLLSTK
EAQVYAVLAELEHHHHHH* 
RmaNOD L20W Q52A 
L56I 60H L101N I105M 
MAPTLSEQTRQLVRASVPAWQKHSVAISATMYRLLFERYPETRSL
FELPERAIHKIASAHLAYARSIDNPSALQAAIRRMVLSHARAGVQA
VHYPLVWECNRDAMKEVLGPDATETLLQAWKEAYDFLAHLLSTK
EAQVYAVLAELEHHHHHH* 
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Spectroscopic Data 
 
Figure S17. 1H NMR of cis-3. 
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Figure S18. 13C NMR of cis-3.  
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Figure S19. 11B NMR of cis-3. 
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Figure S 20.. 1H NMR of trans-3. 
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Figure S21. 13C NMR of trans-3. 
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Figure S22. 11B NMR of trans-3. 
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Figure S23. 1H NMR of cis-4. 
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Figure S24. 13C NMR of cis-4. 
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Figure S25. 11B NMR of cis-4. 
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Figure S26. 19F NMR of cis-4. 
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Figure S27. 1H NMR of cis-5a. 
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Figure S28. 13C NMR of cis-5a. 
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Figure S29. 1H NMR of crude trans-5a. 
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Figure S30. 1H NMR of cis-5b. 
S59 
 
 
Figure S31. 13C NMR of cis-5b. 
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Figure S32. 19F NMR of cis-5b. 
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Figure S33. 1H NMR of crude trans-5b. 
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Figure S34. 1H NMR of cis-5c. 
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Figure S35. 13C NMR of cis-5c. 
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Figure S36. 1H NMR of cis-5d. 
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Figure S37. 13C NMR of cis-5d.
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